119 related articles for article (PubMed ID: 10026857)
1. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy.
Karle P; Müller P; Renz R; Jesnowski R; Saller R; von Rombs K; Nizze H; Liebe S; Günzburg WH; Salmons B; Löhr M
Adv Exp Med Biol; 1998; 451():97-106. PubMed ID: 10026857
[TBL] [Abstract][Full Text] [Related]
2. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors.
Müller P; Jesnowski R; Karle P; Renz R; Saller R; Stein H; Püschel K; von Rombs K; Nizze H; Liebe S; Wagner T; Günzburg WH; Salmons B; Löhr M
Ann N Y Acad Sci; 1999 Jun; 880():337-51. PubMed ID: 10415878
[TBL] [Abstract][Full Text] [Related]
3. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450.
Löhr M; Müller P; Karle P; Stange J; Mitzner S; Jesnowski R; Nizze H; Nebe B; Liebe S; Salmons B; Günzburg WH
Gene Ther; 1998 Aug; 5(8):1070-8. PubMed ID: 10326030
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
Chen L; Waxman DJ
Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
[TBL] [Abstract][Full Text] [Related]
5. Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer.
Mercadé E; Cascalló M; Carrió M; Calbó J; Gómez-Treviño A; Fillat C; Gómez-Foix AM; Mazo A
Ann Oncol; 2001 Mar; 12(3):379-88. PubMed ID: 11332152
[TBL] [Abstract][Full Text] [Related]
6. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide.
Samel S; Keese M; Lux A; Jesnowski R; Prosst R; Saller R; Hafner M; Sturm J; Post S; Löhr M
Cancer Gene Ther; 2006 Jan; 13(1):65-73. PubMed ID: 16096652
[TBL] [Abstract][Full Text] [Related]
7. Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
Samel S; Löhr M
Cancer Treat Res; 2007; 134():469-82. PubMed ID: 17633075
[TBL] [Abstract][Full Text] [Related]
8. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.
Löhr M; Hoffmeyer A; Kröger J; Freund M; Hain J; Holle A; Karle P; Knöfel WT; Liebe S; Müller P; Nizze H; Renner M; Saller RM; Wagner T; Hauenstein K; Günzburg WH; Salmons B
Lancet; 2001 May; 357(9268):1591-2. PubMed ID: 11377651
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
10. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
[TBL] [Abstract][Full Text] [Related]
12. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
Karle P; Renner M; Salmons B; Günzburg WH
Cancer Gene Ther; 2001 Mar; 8(3):220-30. PubMed ID: 11332993
[TBL] [Abstract][Full Text] [Related]
13. Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century.
Löhr M; Hummel F; Faulmann G; Ringel J; Saller R; Hain J; Günzburg WH; Salmons B
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S21-4. PubMed ID: 12042985
[TBL] [Abstract][Full Text] [Related]
14. A clinical protocol for treatment of canine mammary tumors using encapsulated, cytochrome P450 synthesizing cells activating cyclophosphamide: a phase I/II study.
Winiarczyk S; Gradski Z; Kosztolich B; Gabler C; König G; Renner M; Saller RM; Prosl H; Salmons B; Günzburg WH; Hain J
J Mol Med (Berl); 2002 Sep; 80(9):610-4. PubMed ID: 12226743
[No Abstract] [Full Text] [Related]
15. Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.
Günzburg WH; Salmons B
Acta Biochim Pol; 2005; 52(3):601-7. PubMed ID: 16175235
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy.
Günzburg WH; Karle P; Renz R; Salmons B; Renner M
Ann N Y Acad Sci; 1999 Jun; 880():326-36. PubMed ID: 10415877
[TBL] [Abstract][Full Text] [Related]
17. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
Kammertoens T; Gelbmann W; Karle P; Alton K; Saller R; Salmons B; Günzburg WH; Uckert W
Cancer Gene Ther; 2000 Apr; 7(4):629-36. PubMed ID: 10811482
[TBL] [Abstract][Full Text] [Related]
18. Small agarose microcapsules with cell-enclosing hollow core for cell therapy: transplantation of Ifosfamide-activating cells to the mice with preestablished subcutaneous tumor.
Sakai S; Hashimoto I; Tanaka S; Salmons B; Kawakami K
Cell Transplant; 2009; 18(8):933-9. PubMed ID: 19500478
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models-A Prelude to Treating Solid Tumours Effectively in Pets and Humans.
Salmons B; Gunzburg WH
Life (Basel); 2023 Dec; 13(12):. PubMed ID: 38137959
[TBL] [Abstract][Full Text] [Related]
20. Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial.
Salmons B; Löhr M; Günzburg WH
J Gastroenterol; 2003 Mar; 38 Suppl 15():78-84. PubMed ID: 12698877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
